strain
creat
passag
time
mice
final
grown
cell
propag
plaqu
assay
cell
previous
describ
cell
grown
maintain
dulbecco
modifi
minim
essenti
medium
dmem
nissui
tokyo
japan
viru
infect
determin
plaqu
assay
previous
describ
purifi
prepar
previous
describ
brief
amplifi
vero
cell
expos
uv
light
purifi
sucros
densiti
gradient
centrifug
portion
purifi
virion
treat
overnight
formalin
assur
safeti
whole
virion
vaccin
anim
studi
carri
protocol
approv
anim
care
use
committe
nation
institut
infecti
diseas
japan
balbc
male
mice
purchas
slc
hamamatsu
japan
charl
river
japan
crj
tokyo
japan
mice
serolog
check
free
infect
pathogen
microorgan
includ
pp
vaccin
recombin
di
mice
sc
immun
unit
pfu
di
neg
control
week
ident
titer
virus
vaccin
whole
inactiv
virion
mice
sc
inject
back
mg
alum
boost
procedur
week
prime
one
week
later
mice
anesthet
xylazin
ketamin
intraperiton
ip
administr
intranas
inocul
unit
cfu
pp
mam
strain
suspend
pb
kept
globe
box
isol
bsl
laboratori
institut
experiment
period
one
day
later
mice
intranas
challeng
salin
previous
describ
three
day
challeng
serum
nasal
lung
lavag
fluid
collect
measur
viral
titer
antibodi
mice
kill
anesthesia
chloroform
bodyweight
mice
measur
everi
day
igg
titer
determin
elisa
previous
describ
neutral
antibodi
titer
determin
previous
describ
briefli
sampl
dilut
twofold
dmem
contain
fetal
bovin
serum
infecti
unit
vesicular
stomat
viru
vsv
protein
mixtur
incub
hr
neutral
incub
mixtur
inocul
onto
vero
cell
seed
plate
infect
determin
count
number
green
fluoresc
protein
gfp
cell
nab
titer
defin
reciproc
highest
dilut
inhibit
infect
observ
cytokin
chemokin
assay
either
use
mous
inflammatori
cytokin
cytometr
bead
array
kit
becton
dickinson
san
jose
ca
usa
use
luminex
system
luminex
co
austin
tx
usa
previous
report
lung
homogen
prepar
describ
dilut
lysi
buffer
virus
includ
materi
complet
inactiv
uv
irradi
min
luminex
system
follow
cytokin
chemokin
measur
mous
cytokin
plex
antibodi
bead
kit
bioscienc
intern
inc
camarillo
ca
usa
fibroblast
growth
factor
basic
factor
chemokin
kc
protein
ip
vascular
endotheli
growth
factor
vegf
studi
sar
vaccin
efficaci
use
recent
establish
murin
sar
model
model
pp
infect
exacerb
lung
pathogenesi
associ
infect
first
examin
protect
efficaci
whole
virion
respect
twelv
mice
group
sc
inocul
alum
alum
pb
alum
control
booster
immun
vaccin
week
infect
pp
intranas
week
later
one
day
infect
pp
mice
intranas
infect
strain
although
pp
low
virul
caus
mild
respiratori
diseas
mice
show
transient
loss
bodyweight
ruffl
hair
day
postinfect
gradual
recov
howev
mice
coinfect
day
pp
infect
sever
weight
loss
show
high
mortal
exacerb
pneumonia
murin
model
sar
control
mice
show
transient
decreas
bodyweight
day
infect
fig
vaccin
mice
recov
origin
weight
infect
wherea
control
mice
alum
continu
lost
weight
die
day
postinfect
second
set
experi
mice
immun
recombin
empti
di
neg
control
week
week
pp
infect
infect
next
day
similar
result
whole
virion
vaccin
describ
mice
vaccin
di
show
transient
minim
clinic
symptom
ruffl
hair
weight
loss
day
infect
fig
left
sever
symptom
continu
observ
period
control
mice
day
viru
infect
mice
suffer
loss
bodyweight
mice
die
exhibit
sever
respiratori
diseas
wherea
none
mice
vaccin
recombin
di
express
protein
die
fig
right
evalu
vaccin
effect
measur
serum
neutral
antibodi
titer
lung
lavag
vaccin
mice
pp
coinfect
vaccin
mice
develop
high
level
igg
neutral
activ
data
shown
shown
figur
high
level
neutral
antibodi
maintain
coinfect
experi
day
day
postinfect
vaccin
mous
group
titer
lung
lavag
high
day
postinfect
decreas
day
fig
blank
column
alum
viru
becam
undetect
day
data
shown
contrast
viru
titer
significantli
reduc
parallel
high
titer
plasma
neutral
antibodi
vaccin
group
fig
therefor
whole
virion
vaccin
vaccinia
vector
express
spike
protein
protect
highli
pathogen
pulmonari
infect
presenc
opportunist
infect
pp
case
furthermor
result
vaccin
suggest
neutral
antibodi
spike
protein
alon
highli
effect
prevent
sar
develop
ami
et
al
demonstr
previous
level
significantli
high
mous
lung
homogen
day
infect
howev
cytokin
becam
undetect
day
postinfect
better
understand
involv
cytokin
lung
pathogenesi
sar
simultan
measur
six
cytokin
lung
lavag
vaccin
unvaccin
mice
day
infect
virus
replic
extens
vaccin
mice
experienc
maximum
weight
loss
shown
figur
increas
product
lung
control
mous
group
alum
strongli
suppress
vaccin
mice
abl
control
viru
replic
increas
product
cytokin
includ
observ
therefor
possibl
play
role
establish
lung
patholog
pp
coinfect
model
known
mani
neutral
antibodi
recogn
domain
rbd
spike
protein
although
domain
domain
also
neutral
epitop
previous
establish
four
monoclon
antibodi
potent
vitro
neutral
activ
among
major
epitop
local
rbd
protein
exhibit
potent
neutral
activ
demonstr
neutral
antibodi
mainli
respons
protect
efficaci
observ
sar
model
mice
administ
ip
pp
infect
shown
figur
mice
treat
recov
loss
bodyweight
resist
fatal
outcom
observ
vaccin
mice
measur
viru
titer
lung
lavag
day
infect
dramat
decreas
accord
concentr
neutral
antibodi
given
fig
level
serum
neutral
antibodi
mice
proport
high
time
point
neutral
activ
low
still
detect
lung
lavag
result
clearli
show
neutral
antibodi
protein
highli
effect
prevent
sar
develop
observ
high
level
product
pp
mous
lung
lavag
day
infect
fig
howev
cytokin
profil
mice
may
variabl
modifi
pp
infect
alon
infect
therefor
measur
cytokin
lung
lavag
protect
unprotect
mice
use
mous
cytokin
antibodi
bead
kit
day
pp
infect
infect
day
day
day
infect
previous
report
product
two
cytokin
increas
day
infect
associ
high
titer
shown
figur
interestingli
product
increas
pp
infect
alon
decreas
day
increas
wherea
increas
infect
cytokin
increas
protect
mice
fig
suggest
import
two
cytokin
lung
pathogenesi
cytokin
profil
shown
figur
c
level
quit
high
infect
day
howev
even
protect
mice
produc
high
level
contrast
macrophag
inflammatori
protein
mip
kc
produc
infect
level
vegf
consist
low
concentr
cytokin
low
limit
detect
data
shown
result
suggest
play
role
lung
pathogen
pp
coinfect
present
studi
evalu
protect
efficaci
sar
vaccin
candid
whole
virion
recombin
di
express
protein
use
murin
model
system
sever
respiratori
diseas
caus
coinfect
pp
result
shown
paper
suggest
whole
virion
vaccin
either
without
formalin
treatment
protect
highli
pathogen
pulmonari
infect
presenc
opportunist
infect
pp
give
infect
mortal
mice
coinfect
pp
dramat
reduc
level
serum
neutral
antibodi
mice
proport
high
viru
titer
lung
lavag
infect
substanti
decreas
accord
concentr
neutral
antibodi
given
therefor
high
titer
neutral
igg
antibodi
protein
system
elicit
vaccin
would
suffici
prevent
sar
develop
treatment
convalesc
plasma
success
use
treat
sar
suggest
passiv
immun
might
use
approach
combat
sar
subbarao
et
al
shown
passiv
transfer
murin
neutral
antibodi
prevent
replic
respiratori
tract
antibodi
shown
neutral
viru
vitro
prevent
viral
replic
mous
model
infect
sui
et
al
investig
antivir
activ
human
monoclon
antibodi
protein
block
receptor
associ
demonstr
prophylact
effect
monoclon
antibodi
vivo
use
mous
model
sar
recent
sever
human
monoclon
antibodi
protein
develop
therapeut
applic
mani
neutral
antibodi
recogn
rbd
spike
protein
domain
domain
also
neutral
epitop
passiv
immun
highli
effect
combin
neutral
antibodi
recogn
sever
epitop
protein
design
viru
escap
mutat
prevent
involv
cytokin
sar
pathogenesi
describ
level
variou
cytokin
chemokin
lung
mice
infect
pp
measur
high
level
product
note
day
follow
coinfect
day
therefor
involv
cytokin
high
pathogenesi
caus
coinfect
pp
sar
cov
suggest
studi
observ
product
increas
day
infect
associ
high
titer
wherea
cytokin
increas
mice
therefor
analyz
kinet
multipl
cytokin
chemokin
product
detail
pp
pp
coinfect
vaccin
mice
although
sever
cytokin
chemokin
ubiquit
temporarili
upregul
lung
inflamm
caus
microb
found
level
profil
product
well
match
diseas
sever
protect
contribut
inflammatori
cytokin
sar
human
need
investig
